AMYLIN Pharmaceuticals has announced positive results from a 28-week Phase 2 dose-ranging study to treat diabetes and obesity.
13/07/2009
VANDA Pharmaceuticals has compiled a report titled the “Common effect of antipsychotics on the biosynthesis and regulation of fatty acids and cholesterol supports a key role of lipid homeostasis in schizophrenia" for Schizophrenia Research, the official journal of the Schizophrenia International Research Society.
13/03/2009
STELLAR Pharmaceuticals has announced the launch of Neovisc Single Dose in the Canadian market.
08/07/2009
NOVABAY Pharmaceuticals has announced preclinical animal data showing that NVC-422, the company's lead Aganocide compound, was effective in treating subcutaneous dermatophyte (skin fungus) infections.
16/03/2009
SAGENT Pharmaceuticals has announced FDA approval of its Azithromycin for Injection therapy developed for treatment of bacterial infections.
31/03/2009
ADDEX Pharmaceuticals, an allosteric modulation company has announced an invitation for its annual Research and Development day on 16 July 2009 in Geneva, Switzerland.
06/07/2009
RANBAXY Laboratories has announced that is has received approval from the Australian health regulator to market its anti-fungal tablets in the country.
13/03/2009
A $28M NURSES support fund has been introduced to the Western Australian health system and will see nurses in public hospitals benefit from improved and enhanced workplace facilities.
13/05/2009
HONG Kong’s International Medical Devices and Supplies Fair has been announced for its fourth year and is set to take place on 4 to 6 November 2009.
21/05/2009
BAYER Healthcare and Regeneron Pharmaceuticals have announced the extension of their VEGF Trap-Eye development program.
06/05/2009
THE FEDERAL Government has announced a range of rebates and funding agreements, designed to give cancer patients better access to treatments and diagnostic tools.
02/07/2009
THE FDA advisory committee have met to discuss the new drug application (NDA) for Bayer’s rivaroxaban.
25/03/2009
The US Food and Drug Administration (FDA) has approved Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years. This new vaccine extends the protection to six more types of the disease-causing bacteria than its predecessor Prevnar.
01/03/2010
MORE than two million Australians living with osteoporosis1 are set to benefit from the first once-a-month osteoporosis therapy, after it was today listed on the Pharmaceutical Benefits Scheme (PBS).
01/07/2009
Bayer has begun a clinical Phase I study to treat non-Hodgkins lymphoma (NHL) using a patient-specific vaccine derived from tobacco plants.
12/02/2010